Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Income from Continuing Operations (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Income from Continuing Operations for 13 consecutive years, with 3016463.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 278.7% year-over-year to 3016463.0, compared with a TTM value of 7557382.0 through Dec 2025, down 43.7%, and an annual FY2025 reading of 8376959.0, down 59.29% over the prior year.
  • Income from Continuing Operations was 3016463.0 for Q4 2025 at Abvc Biopharma, down from 1287523.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 487431.0 in Q3 2024 and bottomed at 6901328.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 2466491.0, with a median of 2000144.5 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations plummeted 409.29% in 2022, then surged 87.01% in 2023.
  • Year by year, Income from Continuing Operations stood at 6901328.0 in 2021, then skyrocketed by 34.78% to 4500902.0 in 2022, then soared by 87.01% to 584641.0 in 2023, then crashed by 36.24% to 796527.0 in 2024, then tumbled by 278.7% to 3016463.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ABVC at 3016463.0 in Q4 2025, 1287523.0 in Q3 2025, and 2309206.0 in Q2 2025.